Disease relevance of Apoa5

• Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants [1].

High impact information on Apoa5

• The expression of apolipoprotein AV was reduced in these mice, implicating FXR in triglyceride regulation [2].
• Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase [3].
• ApoAV has been discovered recently as a novel modifier of triglyceride (TG) metabolism, but the pathways involved are currently unknown [4].
• ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis [4].
• These findings suggest a role of ApoA-V in regulating levels of circulating triglycerides and cholesterol [5].

Biological context of Apoa5

• However, rat Apoa5 gene contains only one intron in contrast with two introns of mouse Apoa5 gene [6].
• To study the role of ApoA-V in triglyceride homeostasis, we compared lipid profiles in mice expressing normal and highly elevated levels of ApoA-V [5].

Associations of Apoa5 with chemical compounds

• Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice [5].

Other interactions of Apoa5

• OBJECTIVE: ApoAV, a newly discovered apoprotein, affects plasma triglyceride level [1].

References